What are the criteria for fulminant hepatitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Criteria for Fulminant Hepatitis

Fulminant hepatitis (acute liver failure) is defined by the presence of coagulation abnormality (INR >1.5 or prothrombin time >24 seconds) combined with any degree of mental alteration (hepatic encephalopathy) in a patient without preexisting cirrhosis, with illness duration less than 26 weeks. 1, 2

Core Diagnostic Criteria

The essential elements that must be present include:

  • Coagulopathy: International Normalized Ratio (INR) >1.5 or prothrombin time >24 seconds, unresponsive to parenteral vitamin K administration 3, 1, 2
  • Hepatic encephalopathy: Any degree of mental status alteration, ranging from subtle confusion to coma 1, 4
  • Absence of preexisting cirrhosis: The patient must have been previously healthy without chronic liver disease 1, 4
  • Acute timeframe: Symptoms developing within 26 weeks of illness onset 1

A more restrictive classical definition specifies encephalopathy occurring within 15 days of jaundice onset 1.

Specific Clinical Presentations by Etiology

Wilson Disease Fulminant Presentation

When fulminant hepatitis occurs due to Wilson disease, a characteristic pattern emerges that differs from other etiologies 3:

  • Coombs-negative hemolytic anemia with acute intravascular hemolysis features 3
  • Modest aminotransferase elevations: Typically <2,000 IU/L (much lower than viral or drug-induced causes) 3
  • Markedly low alkaline phosphatase: Typically <40 IU/L 3
  • Alkaline phosphatase to bilirubin ratio <2 (alkaline phosphatase in IU/L divided by total bilirubin in mg/dL) 3
  • Rapid progression to renal failure 3
  • Female predominance: 2:1 female to male ratio 3

Autoimmune Hepatitis Fulminant Presentation

The acute severe presentation of autoimmune hepatitis may lack typical chronic features 3:

  • Normal serum IgG in 25-39% of cases 3
  • Absent or weak ANA in 29-39% of cases 3
  • Centrilobular hemorrhagic necrosis with lymphoplasmacytic infiltration on histology 3
  • Heterogeneous hypoattenuated areas on unenhanced CT scan in 65% of cases 3

Laboratory Findings

Beyond the mandatory coagulopathy, additional laboratory abnormalities typically include:

  • Elevated serum aminotransferases: Usually >2.5 times upper limit of normal, though this varies by etiology 3, 2
  • Hyperbilirubinemia: Often marked elevation 2
  • Factor V levels: Useful for monitoring progression 5

Prognostic Indicators

Certain features at presentation predict worse outcomes and need for transplantation 2:

  • Time to encephalopathy >7 days from first symptom (versus <7 days) 2
  • Prothrombin time >55 seconds on admission 2
  • Lower ALT levels (≤2,384 IU/L) paradoxically indicate worse prognosis 2
  • Higher bilirubin levels on admission 2

Critical Pitfalls to Avoid

The relatively modest aminotransferase elevations in some fulminant cases (particularly Wilson disease) often lead clinicians to underestimate disease severity 3. Do not be falsely reassured by ALT/AST levels that seem "not that high"—the coagulopathy and encephalopathy define the severity, not the transaminases 3, 2.

In acute severe autoimmune hepatitis, the absence of typical autoantibodies and normal IgG levels may delay diagnosis 3. Liver biopsy showing plasmacytic infiltration should prompt consideration of this diagnosis even when serologic markers are negative 3.

References

Guideline

Management of Acute Fulminant Hepatitis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Fulminant hepatic failure: summary of a workshop.

Hepatology (Baltimore, Md.), 1995

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.